Sotio partners with Merck to test lead candidate with Keytruda; DC’s KeifeRx raises $6M in Series A — and brings on two new board members
Sotio has been on a roll lately. The quiet Czech biotech based in Prague got a massive $315 million raise last week, and now the biotech announced today that it’s joined in on a collaboration with Merck to evaluate a combo of Sotio’s lead candidate SOT101 with Merck’s PD-1 antibody Keytruda.
- | SOTIO
Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial
Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround.
- | MeiraGTx
MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom
- | Windtree Therapeutics
Windtree Therapeutics CEO Craig Fraser – Breaking Down Acute Heart Failure (Video)
Windtree Therapeutics CEO Craig Fraser is a military vet with 30 years experience in biotech, including at Pfizer and J&J.
- | Cerevance
Cell-Type-Specific Analyses
Guide Efforts against Brain Disease
Cerevance is working to change that. Proprietary
technology that accurately determines brain age and
relates it to Alzheimer’s, Parkinson’s, and other brain
diseases is providing novel insights that inform therapeutic development
- | DURECT
Epigenetic Therapies Start Operating Outside the Lines
Durect focuses on eliminating the epigenetic faults that cause cells to become dysfunctional. Following this approach, Durect intends to generate drugs that can treat acute organ injury and chronic liver diseases.
- | SOTIO
Little European biotech Sotio nabs a super $316M funding round for its superagonist work
Sotio is also working on earlier efforts, including BOXR1030, its next-gen CAR-T program for solid tumors expressing GPC3 and based on its so-called BOXR platform “that aims to enhance the fitness of T cells in the hostile tumor microenvironment,” according to the Prague-based company.
- | Sio Gene Therapies
Rare disease with fatal diagnosis doesn’t stop this woman from living life – and helping others
Last month, Jessie Jackson’s friends and family sang her happy birthday a little early. Jessie doesn’t turn 30 until Dec. 12, but for the past five years on the anniversary of her diagnosis, her parents have hosted a fundraiser. They weren’t taking any chances.
